The paper described the results of 12 patients with rectal cancer, all of whom saw their cancer vanish after treatment with dostarlimab. Participants received a dose of dostarlimab every three. After the second dose, 8.3% (1 out of 12) of participants who received 10 μg BNT162b1 and 75.0% (9 out of 12) of participants who received 30 μg BNT162b1 reported fever of ≥38.0 °C. On the.